Six Scientists From Top Academic And Medical Centers Join Elysium Health's™ Scientific Advisory Board, Composed Of More Than 35 Members, Including Six Nobel Laureates, To Help Pursue The Study Of Natural Compounds For Consumer Health

Elysium Health plans to initiate a clinical trial on its first product BASIS™, which targets DNA repair, cellular detoxification, energy production and protein function

Company launches new website to support next wave of growth

Aug 20, 2015, 09:00 ET from Elysium Health LLC

NEW YORK, Aug. 20, 2015 /PRNewswire/ -- Elysium Health LLC, a provider of a new category of scientifically validated dietary supplements, today announced that six leading scientists have joined the company's scientific advisory board (SAB) to help pursue the study of natural compounds. The SAB now includes more than 35 industry innovators, scientific researchers, health care experts and clinicians, including six Nobel laureates. At the same time, Elysium Health plans to initiate a clinical trial on its first product BASIS™, an advanced daily supplement designed to target metabolic repair and optimization. 

The new members of the SAB are responsible for many important scientific discoveries and advancements in epidemiology, genomics, and cellular and molecular medicine. Their involvement in Elysium Health is intended to advance the overall development of effective, safe and scientifically sound dietary supplements. The new members include:

  • Arnold Kriegstein, Director, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at University of California, San Francisco
  • Dariush Mozaffarian, Dean, Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy at Tufts University
  • Donald Miller, Associate Professor in Nutrition and Pharmaco-Epidemiology at Boston University
  • Sir Richard Roberts, Chief Scientist at New England Biolabs; recipient of the 1993 Nobel Prize in Physiology or Medicine
  • Eric Schadt, Chair, Department of Genetics and Genomic Sciences at Mount Sinai; Director, Icahn Institute for Genomics and Multiscale Biology
  • Meir Stampfer, Professor of Epidemiology and Nutrition at the Harvard School of Public Health
  • Ajit Varki, Distinguished Professor of Medicine and Cellular & Molecular Medicine at University of California, San Diego; Co-Director, UCSD/Salk Center for Academic Research and Training in Anthropogeny

"Our advisory board is truly unprecedented in the industry, with its deep knowledge, expertise and passion for scientific innovation," said Dr. Leonard Guarente, co-founder and chief scientist of Elysium Health, who has led research efforts at the Massachusetts Institute of Technology (MIT) for 34 years and serves as the director of the Glenn Laboratory for the Science of Aging. "We look forward to working with our new members, and the rest of the advisory board, to share knowledge and research findings, collaborate on news discoveries, and identify natural compounds that may help sustain health."

Elysium Health launched in February with the introduction of BASIS, a daily supplement for metabolic health that contains two compounds – nicotinamide riboside and pterostilbene – that help with metabolic processes such as energy production, sleep cycles, and cognition. The company plans to initiate a placebo-controlled, double-blind, randomized study evaluating BASIS that will focus on overall quality of life with specific measures related to metabolic health. The trial will follow 120 people and Elysium Health plans to initiate it in the third quarter of 2015.

"We are committed to the highest levels of scientific rigor and as such we are pursuing a clinical study. The data will add to the already extensive body of scientific literature around the two active compounds in BASIS," said Eric Marcotulli, co-founder and chief executive officer of Elysium Health. "The trial underscores our commitment to offering people dietary supplements supported by legitimate data and research. We look forward to bringing more scientifically sound consumer health products to market in the next 12 to 18 months that support metabolic and cellular health, as well as enhance biological functions such as muscle repair and brain health."

Since the company's launch in February, thousands of customers have purchased BASIS and opted into a monthly subscription, available exclusively through Elysium's Health re-designed website (www.elysiumhealth.com). The site serves as an online platform where customers can purchase BASIS, access additional scientific information related to the ingredients of BASISand its biological targets/mechanisms of action, as well as learn more about existing customers' experiences with BASIS.

"We are incredibly pleased that consumers have shown a strong interest in not just BASIS but in the scientific information and opportunities for dialogue we provide," said Dan Alminana, co-founder and chief operating officer of Elysium Health. "We have received a lot of unsolicited positive feedback from our customers, and we look forward to continuing to build a true dialogue and partnership with them in support of health and wellness." 

About Elysium Health LLC
Working directly with the world's leading scientists and clinicians, Elysium Health translates advances in science, research and technology into effective, scientifically sound dietary supplements that target biological deficiencies through new pathways that complement diet and exercise.  Elysium Health makes its products available exclusively through its online platform, www.elysiumhealth.com.  Visit Elysium Health at:
Website: www.elysiumhealth.com 
Twitter: @elysiumhq
Facebook: facebook.com/elysiumhealth

SOURCE Elysium Health LLC



RELATED LINKS

http://www.elysiumhealth.com